Skip to content

7:50 am Chair’s Opening Remarks

Navigating NASH: What do we Know Now & How Have we Got Here?

8:00 am NASH in 2020: What Have we Learned & How will we React?

8:30 am Panel Discussion: How Should we Rethink Our Approach to NASH: Collating Lessons Learned for Future Decisions

  • Jason Campagna Chief Medical Officer, Intercept
  • Scott Friedman Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, Icahn School of Medicine at Mount Sinai
  • Peter Traber Partner, Alacrita Consulting
  • Stephen Rossi Vice President, Early Clinical Development, CymaBay Therapeutics
  • Joanne Imperial Vice President, Clinical Research, Blade Therapeutics

9:00 am Setting up Sites for Success

  • Adrienne Stoudenmire Director, Project Management, Cardiovascular/Metabolic Therapeutic Group, ICON

9:30 am Speed Networking

10:15 am Morning Break

12:30 pm Lunch & Networking

3:45 pm Afternoon Break & Networking

Tackling Translation: How we’ve Progressed & How Far we Have to go

4:30 pm The End of the Beginning in NASH Therapy; Ongoing Challenges

  • Scott Friedman Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, Icahn School of Medicine at Mount Sinai

5:00 pm Session held by Siemens Healthineers

Should we Consider NASH the Liver Manifestation of Diabetes & Employ a More Systemic Approach to Targeting Disease?

5:30 pm Panel Discussion: Is the Cure for NASH Better Treatment of Obesity?